Suppr超能文献

阻断组蛋白赖氨酸 79 甲基转移酶 DOT1L 通过抑制肾成纤维细胞激活和上皮-间充质转化减轻肾纤维化。

Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

机构信息

Department of Medicine, Rhode Island Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA.

Department of Clinical Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

出版信息

FASEB J. 2019 Nov;33(11):11941-11958. doi: 10.1096/fj.201801861R. Epub 2019 Aug 2.

Abstract

Disruptor of telomeric silencing-1 like (DOT1L) protein specifically catalyzes the methylation of histone H3 on Lys79 (H3K79) and is implicated in tumors. But its role in tissue fibrosis remains unclear. Here we demonstrated that injury to the kidney increased DOT1L expression and H3K79 dimethylation in renal tubular epithelial cells and myofibroblasts in a murine model of unilateral ureteral obstruction. Administration of EPZ5676, a highly selective inhibitor of DOT1L, attenuated renal fibrosis. Treatment with EPZ5676 or DOT1L small interfering RNA also inhibited TGF-β1 and serum-induced activation of renal interstitial fibroblasts and epithelial-mesenchymal transition (EMT) . Moreover, blocking DOT1L abrogated injury-induced epithelial G/M arrest; reduced expression of Snail, Twist, and Notch1; and inactivated several profibrotic signaling molecules in the injured kidney, including Smad3, epidermal growth factor receptor, platelet-derived growth factor receptor, signal transducer and activator of transcription 3, protein kinase B, and NF-κB. Conversely, DOT1L inhibition increased expression of phosphatase and tensin homolog, a protein associated with dephosphorylation of tyrosine kinase receptors, and prevented decline in levels of Klotho and Smad7, 2 renoprotective factors. Thus, our data indicate that targeting DOT1L attenuates renal fibrosis through inhibition of renal fibroblasts and EMT by suppressing activation of multiple profibrotic signaling pathways while retaining expression of renoprotective factors.-Liu, L., Zou, J., Guan, Y., Zhang, Y., Zhang, W., Zhou, X., Xiong, C., Tolbert, E., Zhao, T. C., Bayliss, G., Zhuang, S. Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

摘要

端粒沉默调节因子 1 样蛋白(DOT1L)蛋白特异性催化组蛋白 H3 赖氨酸 79 的甲基化(H3K79),并与肿瘤有关。但其在组织纤维化中的作用尚不清楚。在这里,我们在单侧输尿管梗阻的小鼠模型中证明,肾脏损伤会增加肾小管上皮细胞和肌成纤维细胞中 DOT1L 的表达和 H3K79 二甲基化。DOT1L 的高度选择性抑制剂 EPZ5676 的给药减轻了肾脏纤维化。用 EPZ5676 或 DOT1L 小干扰 RNA 治疗也抑制了 TGF-β1 和血清诱导的肾间质成纤维细胞和上皮-间充质转化(EMT)的激活。此外,阻断 DOT1L 消除了损伤诱导的上皮 G/M 阻滞;降低了 Snail、Twist 和 Notch1 的表达;并使受损肾脏中几种促纤维化信号分子失活,包括 Smad3、表皮生长因子受体、血小板衍生生长因子受体、信号转导和转录激活因子 3、蛋白激酶 B 和 NF-κB。相反,DOT1L 抑制增加了与酪氨酸激酶受体去磷酸化相关的磷酸酶和张力蛋白同系物的表达,并防止 Klotho 和 Smad7 水平下降,这两种肾保护因子。因此,我们的数据表明,通过抑制多个促纤维化信号通路的激活,同时保留肾保护因子的表达,靶向 DOT1L 可通过抑制肾成纤维细胞和 EMT 来减轻肾脏纤维化。

相似文献

3
Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.
FASEB J. 2019 Jul;33(7):8249-8262. doi: 10.1096/fj.201801067RR. Epub 2019 Apr 5.
5
Inhibition of MLL1-menin interaction attenuates renal fibrosis in obstructive nephropathy.
FASEB J. 2023 Jan;37(1):e22712. doi: 10.1096/fj.202100634RRR.
6
Protein arginine methyltransferase 1 mediates renal fibroblast activation and fibrogenesis through activation of Smad3 signaling.
Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F375-F387. doi: 10.1152/ajprenal.00487.2019. Epub 2019 Dec 9.
7
Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis.
FASEB J. 2020 Jun;34(6):7295-7310. doi: 10.1096/fj.201903254R. Epub 2020 Apr 12.
8
Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.
Kidney Int. 2016 Jan;89(1):147-57. doi: 10.1038/ki.2015.291. Epub 2016 Jan 4.
9
Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.
J Am Soc Nephrol. 2016 Jul;27(7):2092-108. doi: 10.1681/ASN.2015040457. Epub 2015 Dec 23.

引用本文的文献

1
Epigenetic histone modifications in kidney disease and epigenetic memory.
Clin Exp Nephrol. 2025 Apr 5. doi: 10.1007/s10157-025-02668-x.
2
The Impact of Klotho in Cancer: From Development and Progression to Therapeutic Potential.
Genes (Basel). 2025 Jan 23;16(2):128. doi: 10.3390/genes16020128.
4
DOT1L protects against podocyte injury in diabetic kidney disease through phospholipase C-like 1.
Cell Commun Signal. 2024 Oct 25;22(1):519. doi: 10.1186/s12964-024-01895-1.
5
PTEN in kidney diseases: a potential therapeutic target in preventing AKI-to-CKD transition.
Front Med (Lausanne). 2024 Aug 6;11:1428995. doi: 10.3389/fmed.2024.1428995. eCollection 2024.
6
Role of Histone Modifications in Kidney Fibrosis.
Medicina (Kaunas). 2024 May 28;60(6):888. doi: 10.3390/medicina60060888.
8
Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead.
Acta Pharm Sin B. 2024 Mar;14(3):1009-1029. doi: 10.1016/j.apsb.2023.10.023. Epub 2023 Nov 4.

本文引用的文献

1
DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
Biomolecules. 2018 Feb 27;8(1):11. doi: 10.3390/biom8010011.
3
RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase.
JCI Insight. 2018 Feb 8;3(3). doi: 10.1172/jci.insight.94979.
4
Renal tubule injury: a driving force toward chronic kidney disease.
Kidney Int. 2018 Mar;93(3):568-579. doi: 10.1016/j.kint.2017.09.033. Epub 2018 Jan 17.
5
Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation.
Inflamm Regen. 2017 Aug 7;37:17. doi: 10.1186/s41232-017-0048-3. eCollection 2017.
6
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.
Cancers (Basel). 2017 May 17;9(5):52. doi: 10.3390/cancers9050052.
7
The systemic nature of CKD.
Nat Rev Nephrol. 2017 Jun;13(6):344-358. doi: 10.1038/nrneph.2017.52. Epub 2017 Apr 24.
8
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.
Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.
9
Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor.
Pathol Int. 2017 May;67(5):235-246. doi: 10.1111/pin.12530. Epub 2017 Apr 10.
10
Epigenetics of kidney disease.
Cell Tissue Res. 2017 Jul;369(1):75-92. doi: 10.1007/s00441-017-2588-x. Epub 2017 Mar 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验